Anti-Suicide Drugs Market to Exhibit a Rise by 4.1% CAGR Between 2019 to 2027 | Coherent Market Insights

The Global Anti-Suicide Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, and Antibiotic Analog) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 3,818.1 million in 2018 and is projected to expand at a CAGR of 4.1% during the forecast period (2019–2027). Novel approved drugs, which are expected to be commercialized post-2020, introduced for the treatment of suicidal ideation is expected to drive the global anti-suicide drugs market growth. Until recently, suicidal ideation has been treated with anti-depressants, anti-anxiety, and anti-psychotic drugs. The trend is expected to continue till the expected launch of Cyclurad by NeruoRx Pharma during the latter half of the forecast period (2019–2027). Cyclurad is a combination of D-cycloserine and Lurasidone indicated for acute suicidal ideation/behavior (ASIB) in bipolar depression. Various other drug candidates are in the pipeline, which are intended for treatment of suicidal ideation in major depressive disorder (MDD).

Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/10

Anti-suicide Drugs – Beacon Light of Life on the Horizon

There are many reasons that lead to suicide such as use of drugs and alcohol though depression remains one of the major healthcare burdens worldwide leading to lower productivity and in severe cases of suicidal tendencies. Drugs such as anti-psychotic and anti-depressant are prescribed that prevent suicidal thoughts and attempts. However, overdose of these drugs can be fatal and therefore, needs to be administered under the direction of a physician. Extensive research related to suicide treatment is expected to provide a better solution to the global population during the latter half of the forecast period (2019-2027). This would improve the outlook of global anti-suicide drugs market and would help in reducing deaths due to suicide.

The global anti-suicide drugs market was valued at US$ 3,818.1 million in 2018 and is expected to witness a moderate CAGR of 4.1% during the forecast period (2019 – 2027).

Quick Buy – Anti-Suicide Drugs Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/10

Figure 1. Global Anti-Suicide Drugs Market, Drug Pipeline Snapshot

Source: Coherent Market Insights Analysis (2017)

Market Dynamics- Drivers

Global Anti-suicide Drugs Market to be on High Growth Trajectory Post Launch of Anti-Suicidal Drug

Increasing launch of novel anti-suicidal drugs is expected to drive growth of the global anti-suicide drugs market during the forecast period. For instance, NeuroRx Pharma has developed a novel anti-suicidal product Cyclurad (D-cycloserine and Lurasidone), which is indicated for Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. The estimated commercialization of the drug post-2020 is expected to be a major breakthrough innovation for the global anti-suicide drugs market. People with major depressive disorder and risk for suicide would greatly benefit from such novel drug therapies.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/anti-suicide-drugs-market-to-surpass-us-48-billion-by-2024-52

Furthermore, increasing research and development activities in ketamine, an anesthetic drug in reducing suicidal thoughts in depressed people, is expected to drive the global anti-suicide drugs market over the forecast period. For instance, in December 2017, a researcher from the Columbia University Medical Center in the U.S. found that administration of low-dose ketamine had a significant results in reduction of suicidal thoughts within 24 hours among 80 depressed adults. Such treatment offers a promising treatment for rapid relief of suicidal thoughts in depressed people.

High Suicidal Rates to Contribute Towards the Positive Anti-Suicide Drugs Market Outlook

Increasing suicidal rates worldwide is expected to drive the global anti-suicide drugs market over the forecast period. According to the World Health Organization (WHO), suicide accounted for 1.4% of the total deaths worldwide in 2012, accounting for around 800 thousand deaths each year. According to the same source, Russia, India, Republic of Korea, Guyana, Lithuania, Sri Lanka, Hungary, Kazakhstan, and Japan are among the nations with high suicidal rates. Emerging nations therefore possess immense opportunity for anti-suicidal drugs. However, being the first ever oral anti-suicidal therapeutic drug, companies are likely to capture the anti-suicide drugs market in developed regions such as North America and Western Europe. This mainly due to rapid adoption of new therapies and accessibility to healthcare facilities in these regions as compared to emerging economies.

Regional Insights

Global Anti-Suicide Drugs Market to Gain Initial Traction in Developed Economies

Among regions, North America and Europe are expected to witness significant growth during the forecast period, owing to high healthcare expenditure on research and development of anti-suicidal drugs in the regions. Moreover, developed regions offer better healthcare infrastructure and are usually early adopters of new therapies. Increasing launch of novel anti-suicidal drug is expected to drive the regional market growth. Moreover, increasing expenditure on healthcare in emerging economies and high prevalence of suicides in these regions is expected to propel the market growth in the near future. Companies are expected to focus on capitalizing on lucrative opportunities in these regions at the turn of the following decade. This would ensure sustained growth for the market in the foreseeable future.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/10

Global Anti-Suicide Drugs Market Share Analysis (%), by Key Players, 2018

Source: Coherent Market Insights Analysis (2019)

Competitive Landscape

Major players operating in the global anti-suicide drugs market include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson.

Table of Contents

1. Research Objective and assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet By Drug Class
     • Market Snippet By Geography
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Epidemiology
   • Healthcare Spending
   • PEST Analysis
   • Pipeline Analysis
   • Anti-Suicide Prevention Campaigns and Programs
4. Global Anti-Suicide Drugs Market, By Drug Class, 2016 – 2027 (US$ Million)
   • Introduction
     • Market Share Analysis, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, 2016 – 2027
     • Segment Trends
   • Anti-Depressant and Anti-Anxiety Drugs
   • Anti-Psychotic Drugs
   • NMDA Antagonist
   • Antibiotic Analog
5. Global Anti-Suicide Drugs Market, By Geography, 2016 – 2027 (US$ Million)
   • Introduction
     • Market Share Analysis, By Region, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, For Regions, 2016 – 2027
   • North America
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • U.S.
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Canada
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
   • Europe
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • U.K.
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Germany
       • Italy
       • France
       • Spain
       • Russia
       • Rest of Europe
   • Asia Pacific
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • China
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • India
       • Japan
       • ASEAN
       • Australia
       • South Korea
       • Rest of Asia Pacific
   • Latin America
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • Brazil
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Mexico
       • Argentina
       • Rest of Latin America
   • Middle East
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • GCC Countries
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Israel
       • Rest of Middle East
   • Africa
     • Market Share Analysis, By Country, 2019 and 2027 (%)
     • Y-O-Y Growth Analysis, By Country, 2016 – 2027
       • Northern Africa
         • Country Trends
         • Market Size and Forecast, By Drug Class, 2016 – 2027 (US$ Million)
       • Central Africa
       • South Africa
6. Competitive Landscape
   • Heat Map Analysis
   • Company Profiles
     • Pfizer, Inc.
       • Company Overview
       • Product Portfolio
       • Financial Performance
       • Key Developments
       • Market Presence
     • AstraZeneca plc
     • Eli Lilly and Company
     • Allergan plc
     • GlaxoSmithkline plc
     • Merck & Co., Inc.
     • H. Lundbeck A/S
     • NeuroRx, Inc.
     • Johnson & Johnson
7. Section
   • References
   • Research Methodology
   • About us and Sales Contact

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837